READ. SCROLL. LISTEN.

Unbiased headlines. Facts, not spin.

Unbiased Headlines is an independently owned news organization. We bring you the facts, not opinions, written fresh from 110+ named sources. Sources linked so you can verify it yourself.

← Back to headlines

CANARX Executive Arrested in Detroit Tunnel in First Federal Criminal Case Against a Drug-Import Funding Program

CANARX Executive Arrested in Detroit Tunnel in First Federal Criminal Case Against a Drug-Import Funding Program
John Thomas Howard, treasurer of Canadian firm CANARX, was arrested Nov. 8 on smuggling, conspiracy and misbranded-drug charges. He is the first defendant in a U.S. criminal case against an "alternative funding program," and an FDA affidavit says the investigation began with a tip about a different company. His brother Bob Howard remains wanted, and both men deny the charges.

Federal agents arrested John Thomas Howard in the tunnel connecting Detroit and Canada on Nov. 8. He is treasurer and a director of CANARX, a healthcare company based in Windsor, Ontario.

Howard is charged with smuggling, conspiracy and importing a misbranded drug for patient use in the United States. His brother Bob Howard, the company's president, is wanted on similar charges. Court records showed last week that he was still being sought.

The case is the first criminal prosecution by U.S. authorities of a company in the "alternative funding program" business, known as AFPs. These firms promise to cut or eliminate prescription drug costs for Americans, typically by sourcing medications from international markets.

The Food and Drug Administration and the Department of Homeland Security say that model is illegal and can put patients at risk. Their concern is drugs made for foreign markets that carry no U.S. regulatory oversight and, in some cases, the danger of counterfeits.

How the case started

A 35-page affidavit from Dustin Dobbs, a special agent with the FDA's Office of Criminal Investigations, lays out the government's account. It is dated Oct. 29 and was unsealed this month.

According to the affidavit, the investigation did not begin with CANARX. It began with a tip about ScriptSourcing, a Bonita Springs, Florida, firm that marketed an international prescription program to self-funded employer health plans.

ScriptSourcing's founder and CEO, Gary Becker, is described on the company's website as a "health insurance and risk management consultant for more than 30 years." The affidavit says the FDA had ScriptSourcing on its radar since at least 2022 over potential drug import violations.

In August 2025, Dobbs posed as someone interested in entering the AFP business and emailed ScriptSourcing to ask whether it was FDA-compliant. A ScriptSourcing employee replied that it was. The employee said the company offered more than 2,000 name-brand specialty medications and worked with more than 3,000 self-funded health plans.

The informant at the center of the case is the CEO of a peer company that authorities say was committing the same import violations. The affidavit's account of how that cooperation led investigators to CANARX is the backbone of the government's case against the Howards.

What the defense says

CANARX, founded in 2002, denies wrongdoing. General counsel Joseph Morris told CNBC last year that the business operated legally and that the company was confident in the safety of the prescriptions it supplied.

Morris said last week that the Howard brothers "deny all the charges against them, will defend vigorously, and expect to be vindicated in court."

The broader industry makes a legal argument as well. AFPs generally say U.S. law allows individuals to import medication for personal use. Authorities say these operations go well beyond that, running organized, commercial import programs for patients and employer plans.

That dispute is the legal heart of the case. A personal-use exception for one person is a different thing from a business that builds a supply pipeline for thousands of plan members. Whether a court sees CANARX's operation as the second is what the charges will test.

What is at stake

Prescription prices are the reason this industry exists. Employers and patients facing high drug bills have been drawn to programs promising steep discounts, and the FDA is now treating the people running those programs as criminal defendants rather than regulatory problems.

The charges are allegations. No verdict exists, and the Howards are entitled to the presumption of innocence. The affidavit has been unsealed, but the defense has yet to answer it in court.

Two questions remain open. John Howard's case must move through the federal courts, and Bob Howard has to be located. Beyond that, other AFPs, including the Florida firm that set the investigation in motion, now know federal agents are paying attention to their business.

Sources used for this briefing

4 links from 2 independent newsrooms (syndicated copies of the same report count once)

These are the sources it draws on, linked so you can verify.

center-left
CNBCCEO turned informant: How the FDA built a case against executives promising cheap medications
unknown
CMoneyCEO turned informant: How the FDA built a case against executives promising cheap medications
unknown
Europe SaysHow FDA built a case against CANARX execs offering cheap medication - United States
unknown
biztocCEO turned informant: How the FDA built a case against executives promising cheap medications